BerGenBio

Report Publication Announcement • Nov 10, 2017

BerGenBio ASA: Invitation to Third Quarter 2017 Results Presentation and Webcast

Bergen, Norway, 10 November 2017 – BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, will announce its results for the third quarter 2017 on Friday, 17 November 2017.

A presentation by BerGenBio's senior management team will take place at 9.00 am CET at:

Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo

Meeting Room: Bjørvika

The presentation will webcast live and the link will be available at www.bergenbio.com in the section Investors/Reports and presentations/Webcasts. A recording will be available shortly after the webcast has finished.

The results report and the presentation will be available at www.bergenbio.com in the section: Investors/Reports and presentations from 7:00 am CET the same day.

-Ends-

Contacts

Richard Godfrey CEO, BerGenBio ASA media@bergenbio.com +47 917 86 304 Tom Henrik Sundby Finance Director, BerGenBio ASA tom.sundby@bergenbio.com +47 477 54 415 David Dible, Mark Swallow, Marine Perrier Citigate Dewe Rogerson bergenbio@citigatedr.co.uk +44 207 638 9571

Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.